Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading Chinese pharmaceutical company, has announced the upcoming initiation of a Phase I clinical study for its investigational drug GenSci125 in the United States. The study is designed to evaluate the drug’s efficacy in luteal supplementation or replacement for assisted reproductive technology (ART).
Progesterone, a crucial drug for maintaining pregnancy in clinical practice, typically requires frequent administrations. GenSci125 represents an innovative approach as the first long-acting progesterone weekly injection to receive FDA approval for clinical trials. This advancement has the potential to significantly reduce the number of clinical administration times compared to short-acting progesterone injections. The company earned approval for a clinical trial in China in December of the previous year.- Flcube.com
